UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

Movement disorders, 2020-06, Vol.35 (6), p.1046-1054

2020

Volltextzugriff (PDF)

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

Annual review of pharmacology and toxicology, 2001-01, Vol.41 (1), p.237-260

2001

Volltextzugriff (PDF)

(3 S )‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent

The Journal of pharmacology and experimental therapeutics, 2020-09, Vol.374 (3), p.404-419

2020

Volltextzugriff (PDF)

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease

Journal of Huntington's disease, 2018-01, Vol.7 (1), p.1-16

2018

Volltextzugriff (PDF)

The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans

European journal of clinical pharmacology, 2012-09, Vol.68 (9), p.1281-1286

2012

Volltextzugriff (PDF)

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Journal of headache and pain, 2020-08, Vol.21 (1), p.99-99, Article 99

2020

Volltextzugriff (PDF)

To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study

European journal of paediatric neurology, 2018-05, Vol.22 (3), p.412-418

2018

Volltextzugriff (PDF)

Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease

The Journal of pharmacology and experimental therapeutics, 2020-07, Vol.374 (1), p.113-125

2020

Volltextzugriff (PDF)

PND47 The Huntington Clinical Self-Reported Instrument (H-CSRI): Validation in Germany, Poland and USA

Value in health, 2011-11, Vol.14 (7), p.A326-A326

2011

Volltextzugriff (PDF)

PND29 VALIDATION OF THE HUNTINGTON CLINICAL SELF-REPORTED INSTRUMENT (H-CSRI), A CLINIMETRIC PATIENT ASSESSED SCALE FOR PATIENTS WITH HUNTINGTON'S DISEASE

Value in health, 2011, Vol.14 (3), p.A207-A207

2011

Volltextzugriff (PDF)

PND38 International Comparison of Huntington Disease (HD) Burden

Value in health, 2011-11, Vol.14 (7), p.A324-A324

2011

Volltextzugriff (PDF)

Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission

The Journal of pharmacology and experimental therapeutics, 2020-07, Vol.374 (1), p.126-133

2020

Volltextzugriff (PDF)

P.l.c.043 ACR325: a dopaminergic stabiliser that displays state-dependent effects in-vivo

European neuropsychopharmacology, 2009, Vol.19, p.S276-S276

2009

Volltextzugriff (PDF)

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

Pharmacology research & perspectives, 2021-05, Vol.9 (3), p.e00792-n/a

2021

Volltextzugriff (PDF)

First‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers

Clinical pharmacology in drug development, 2021-12, Vol.10 (12), p.1485-1494

2021

Volltextzugriff (PDF)

Extrastriatal dopamine D 2 receptor binding in Huntington's disease

Human brain mapping, 2011-10, Vol.32 (10), p.1626-1636

2011

Volltextzugriff (PDF)

The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model

European journal of pharmacology, 2013-01, Vol.698 (1-3), p.278-285

2013

Volltextzugriff (PDF)

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

NPJ Parkinson's Disease, 2018, Vol.4 (1), p.35-5, Article 35

2018

Volltextzugriff (PDF)

F10 Correlations between functional measures, voluntary and involuntary motor symptoms in HD -multivariate analysis of cross-sectional and longitudinal registry data

Journal of neurology, neurosurgery and psychiatry, 2010-09, Vol.81 (Suppl 1), p.A25-A26

2010

Volltextzugriff (PDF)

DA stabilisers — fourth generation antipsychotic drugs

SCHIZOPHRENIA RESEARCH, 2003, Vol.60 (1), p.119-119

2003

Volltextzugriff (PDF)

Poster 19: Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington's Disease Rating Scale (UHDRS) Motor Score

Neurotherapeutics, 2010-01, Vol.7 (1), p.144-144

2010

Volltextzugriff (PDF)

PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson’s Disease

Neuropharmacology, 2002-10, Vol.43 (5), p.817-824

2002

Volltextzugriff (PDF)

Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder

Behavioral and brain functions, 2006-12, Vol.2 (1), p.40-40

2006

Volltextzugriff (PDF)

F03 Huntington Quality Of Life Interview (HQOLI): a new huntington's disease-specific quality of life instrument

Journal of neurology, neurosurgery and psychiatry, 2010-09, Vol.81 (Suppl 1), p.A23-A23

2010

Volltextzugriff (PDF)

Poster 21: EURO-HDB—The First Large, Comprehensive European Study on the Burden of Huntington's Disease

Neurotherapeutics, 2010-01, Vol.7 (1), p.145-145

2010

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(87)
Schwedisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

(3 S )‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease

The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study

Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease

PND47 The Huntington Clinical Self-Reported Instrument (H-CSRI): Validation in Germany, Poland and USA

PND29 VALIDATION OF THE HUNTINGTON CLINICAL SELF-REPORTED INSTRUMENT (H-CSRI), A CLINIMETRIC PATIENT ASSESSED SCALE FOR PATIENTS WITH HUNTINGTON'S DISEASE

PND38 International Comparison of Huntington Disease (HD) Burden

Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission

P.l.c.043 ACR325: a dopaminergic stabiliser that displays state-dependent effects in-vivo

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

First‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers

Extrastriatal dopamine D 2 receptor binding in Huntington's disease

The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

F10 Correlations between functional measures, voluntary and involuntary motor symptoms in HD -multivariate analysis of cross-sectional and longitudinal registry data

DA stabilisers — fourth generation antipsychotic drugs

Poster 19: Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington's Disease Rating Scale (UHDRS) Motor Score

PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson’s Disease

Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder

F03 Huntington Quality Of Life Interview (HQOLI): a new huntington's disease-specific quality of life instrument

Poster 21: EURO-HDB—The First Large, Comprehensive European Study on the Burden of Huntington's Disease

Aktive Filter

Suchergebnisse filtern